Skip to main content
. 2017 May 16;16:65. doi: 10.1186/s12933-017-0547-1

Fig. 3.

Fig. 3

Illustration of potential synergistic effects of SGLT2 inhibitor with DPP-4 inhibitor in DKD therapy. SGLT2i Sodium–glucose co-transporter 2 inhibitor, DPP-4i dipeptidyl peptidase-4 inhibitor, UGE urinary glucose excretion, GLP-1 glucagon-like peptide-1, GIP glucose-dependent insulinotropic polypeptide, SBP systolic blood pressure, DKD diabetic kidney disease